Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1213 Innsbruck Dr SUNNYVALE CA 94089-1317 |
Tel: | 1-415-3095999 |
Website: | https://silkroadmed.com |
IR: | See website |
Key People | ||
Charles S. McKhann Chief Executive Officer, Director | Lucas W. Buchanan Chief Financial Officer, Chief Operating Officer | Kevin M. Klemz Executive Vice President, Chief Legal Officer, Secretary | Richard M. Ruedy Executive Vice President - Regulatory Affairs, Clinical Affairs and Quality Assurance |
Business Overview |
Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations. |
Financial Overview |
For the fiscal year ended 31 December 2023, Silk Road Medical Inc revenues increased 28% to $177.1M. Net loss increased 1% to $55.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling, general and administrative increase of 18% to $115.4M (expense), Stock-based Compensation in SGA increase of 59% to $29.6M (expense). |
Employees: | 474 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $576.57M as of Dec 31, 2023 |
Annual revenue (TTM): | $177.13M as of Dec 31, 2023 |
EBITDA (TTM): | -$56.57M as of Dec 31, 2023 |
Net annual income (TTM): | -$55.74M as of Dec 31, 2023 |
Free cash flow (TTM): | -$33.52M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 39,174,619 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |